Perspective Therapeutics News

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Futu NewsJan 16 19:33

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16

Futu NewsJan 16 10:31

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Futu NewsJan 15 22:31

Perspective Therapeutics' Strategic Advancements and Positive Clinical Developments Justify Buy Rating

TipRanksJan 15 22:26

RBC Capital Reiterates Outperform on Perspective Therapeutics, Maintains $16 Price Target

BenzingaJan 15 00:45

Perspective Therapeutics Analyst Ratings

BenzingaJan 15 00:44

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating

Futu NewsJan 14 20:36

Perspective Therapeutics (CATX) Receives a Buy From Truist Financial

TipRanksJan 14 20:21

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 25, 2024 23:56

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Futu NewsNov 25, 2024 23:33

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Futu NewsNov 25, 2024 20:31

RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk

MT NewswiresNov 25, 2024 20:08

Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns

TipRanksNov 25, 2024 19:08

Perspective Therapeutics Is Maintained at Outperform by Oppenheimer

Dow JonesNov 22, 2024 22:32

Perspective Therapeutics Analyst Ratings

BenzingaNov 22, 2024 22:22

Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Futu NewsNov 22, 2024 21:31

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Futu NewsNov 22, 2024 20:32

Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)

TipRanksNov 22, 2024 20:24

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Futu NewsNov 22, 2024 07:32

Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results

TipRanksNov 22, 2024 07:09